<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02368743</url>
  </required_header>
  <id_info>
    <org_study_id>000179</org_study_id>
    <nct_id>NCT02368743</nct_id>
  </id_info>
  <brief_title>QUality of Life in pAtients With Mild to modeRate Active procTitis Treated by mesalaZine (Pentasa®)</brief_title>
  <acronym>QUARTZ</acronym>
  <official_title>QUality of Life in pAtients With Mild to modeRate Active procTitis Treated by mesalaZine (Pentasa®)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      This national, observational and multicentre study aims at establishing a picture of real
      clinical practices management among patients treated with Pentasa®, according to the current
      therapeutic strategy in proctitis or distal proctosigmoiditis. This study should be able to
      provide data on patients' health related quality of life, compliance and efficacy in real
      clinical practice
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Anticipated">May 31, 2018</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Short Inflammatory Bowel Disease Questionnaire (SIBDQ) total score</measure>
    <time_frame>From baseline to week 8</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">117</enrollment>
  <condition>Distal Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>mesalazine</arm_group_label>
    <description>Treatment according to standard clinical practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mesalazine</intervention_name>
    <arm_group_label>mesalazine</arm_group_label>
    <other_name>Pentasa®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Gastroenterologists with private and/or hospital practice
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient aged 18 years or older.

          -  Patient suffering from mild to moderate active proctitis or distal proctosigmoiditis
             (MAYO score ≥ 3 and ≤ 10) at inclusion based on clinical and endoscopic findings
             within 6 months before study inclusion.

          -  Patient with evidence of endoscopic active proctitis or distal proctosigmoiditis
             (Montreal classification E1 or E2 defined by an involvement not exceeding 25 cm from
             the anal margin) within 6 months before study inclusion.

          -  Treatment of the current flare with Pentasa® to induce a remission initiated by the
             patient, the general practitioner or the gastroenterologist, during the inclusion
             visit or during the week before the inclusion visit.

          -  Patient having received oral and written information on the study, without any
             objections for the use of his/her personal data, and having signed a written Informed
             Consent Form.

        Exclusion Criteria:

          -  Patient included in an interventional study assessing treatment for active proctitis
             or distal proctosigmoiditis.

          -  Patient with left sided, colitis or pancolitis.

          -  Patient with severe proctitis (MAYO score ≥ 11 at inclusion).

          -  Patient previously treated with biologics.

          -  Patient treated with immunosuppressive within 1 month before study inclusion.

          -  Patient treated with corticosteroids within 2 weeks before study inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gastro-Entérologie et Hépatologie - CHU Brabois (there may be other sites in this country)</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2015</study_first_submitted>
  <study_first_submitted_qc>February 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2015</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Proctitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

